Eriocalyxin B

SKU: orb1297382

Description

Eriocalyxin B is a covalent STAT3 inhibitor that induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma via caspase- and p53-dependent pathways. Its efficacy, demonstrated in vitro, supports its investigation as a candidate therapeutic agent for STAT3-dependent cancers.

Research Area

Cell Biology, Immunology & Inflammation, Metabolism Research, Molecular Biology, Pharmacology & Drug Discovery, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 84745-95-9
• MW: 344.4
• Purity: 99.35% (May vary between batches)
• Formula: C₂₀H₂₄O₅
• SMILES: [H][C@@]12C[C@@]3(C(=O)C1=C)[C@@]([H])(CC2)[C@@]12CO[C@]3(O)[C@@H](O)[C@]1([H])C(C)(C)C=CC2=O
• Target: NF-κB|||Apoptosis|||cAMP|||STAT
• Solubility: DMSO:55 mg/mL (159.7 mM)

Bioactivity

• In Vitro:
  In this study, we demonstrated that Eriocalyxin B was efficacious in experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. Treatment with Eriocalyxin B led to amelioration of EAE, which correlated with reduced spinal cord inflammation and demyelination. Eriocalyxin B treatment abolished encephalitogenic T-cell responses to myelin oligodendrocyte glycoprotein in an adoptive transfer EAE model. The underlying mechanism of Eriocalyxin B-induced effects involved inhibition of T helper (Th) 1 and Th17 cell differentiation through Janus Kinase/Signal Transducer and Activator Of Transcription and Nuclear factor-κB signaling pathways as well as elevation of reactive oxygen species
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

STAT, cAMP, Apoptosis, inhibit, p65, NFkB, NF-kB, NFκB, Eriocalyxin B, Inhibitor

Compound Identifiers

PubChem CID

16202215